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ABSTRACT
Introduction: Elderly people and adults with 
chronic disease or compromised immune 
status are at increased risk of pneumococcal 
infection, with pneumonia being the most 
common serious presentation and a significant 
cause of morbidity and mortality. Most 
European countries have recommendations for 
pneumococcal vaccination but vaccination rates 
have remained low. In the present article, the 
authors present the results of a European survey 
that investigated the current level of awareness 
of pneumococcal infection among primary 
care physicians and specialists, and attitudes to 
vaccination in these physicians and members of 
the general public aged >50 years. 
Methods: Primary care physicians (n = 1,300) and 
specialists (n = 926) from 13 Western European 
countries participated in online/face-to-face 
interviews, and a further 6,534 individuals aged 
>50 years from a population sample reflecting 
local socio-demographic structure participated 
in telephone/face-to-face interviews. 
Results: Pneumonia was the most well-known of 
the pneumococcal infections amongst primary 
care physicians and specialists. However, there 
was a relatively low awareness of the term 
invasive pneumococcal disease (IPD), with only 
50% of primary care physicians and 71% of 
specialists reporting knowledge of the term IPD. 
Key factors influencing a physician’s decision to 
prescribe pneumococcal vaccination were the 
patient’s health condition, recommendations 
from health authorities, and the tolerability of 
the vaccine. Perceptions regarding vaccination 
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The clinical spectrum of pneumococcal 
infections ranges from sinusitis and acute 
otitis media through to pneumonia and 
meningitis, with pneumonia being the most 
common serious presentation in adults [5, 7]. 
Pneumococcal infections are classified as 
invasive pneumococcal disease (IPD) if 
Streptococcus pneumoniae is isolated from a 
normally sterile site such as the bloodstream or 
meninges [7]. Therefore, IPD is a microbiological 
rather than a clinical diagnosis, requiring 
specific testing usually within a secondary (i.e., 
hospital) setting. The term IPD is predominantly 
used by epidemiologists, vaccinologists, 
and paediatricians. Bacteraemic pneumonia 
is the most common IPD, comprising the 
overwhelming majority of adult cases [8–10].
S. pneumoniae is a leading cause of community-
acquired pneumonia (CAP; i.e., pneumonia 
in individuals who have not been recently 
hospitalised) and thus most of the burden of 
serious pneumococcal infection in adults relates 
to pneumonia [5, 7]. The incidence of CAP varies 
across both studies and countries; however, 
publications consistently report increasing 
incidence with increasing age [5, 11]. Therefore, as 
the mean age of the population increases within 
Europe, it is expected that the burden of CAP is 
likely to increase. The burden of pneumococcal 
infections is also exacerbated by increasing 
numbers of individuals with chronic disease or 
HIV infection [12–15], and has remained high 
in adults aged >50 years despite the use of the 
23-valent purified capsular polysaccharide 
vaccine (PPV-23) in adults and the pneumococcal 
conjugate vaccine (PCV) in children [16]. 
The reported overall incidence of IPD in 
children and adults ranges from 10 to 23.2 per 
100,000 in US and European studies conducted 
between 1995 and 2007, rising from 16.2 to 59.7 
per 100,000 and 97 per 100,000 in adults aged 
≥65 and ≥90 years, respectively [9, 10, 17–20]. 
were good amongst the members of the general 
public; individuals did not fear vaccines or their 
side effects. The main drivers for vaccination were 
recommendations from a healthcare professional 
and, to a lesser extent, that vaccination provides 
reassurance against contracting a disease. 
Conclusion: These findings highlight the low 
awareness of the term IPD in comparison with 
individual pneumococcal conditions. Given the 
importance of physician recommendations in 
encouraging patients to be vaccinated, primary 
care physicians need to be vigilant of patients 
at risk of pneumococcal infections in order to 
increase vaccination rates.
Keywords: Europe; Immunology; Infectious 
diseases; Invasive pneumococcal disease; 
Pneumococcal infection; Survey; Vaccination
INTRODUCTION
Infectious diseases in elderly people are a 
significant cause of morbidity and mortality 
in Europe in spite of the availability of 
antibiotics and vaccines for conditions such 
as pneumococcal infections, influenza, herpes 
zoster, and hepatitis A and B [1–5]. Multiple 
changes occur with age in both innate and 
adaptive immune systems, and this waning 
immunity (known as ‘immunosenescence’) as 
well as physiological changes associated with 
ageing make elderly individuals especially 
vulnerable to infectious diseases [2, 6]. 
Pneumonia and influenza, in particular, tend to 
occur with greater severity in elderly individuals 
than in younger adults and are associated with 
poorer outcomes [4]. Adult populations at 
increased risk of pneumococcal infection are the 
elderly, those with chronic disease, such as lung 
or heart disease, diabetes, sickle cell anaemia, or 
asplenia, and those with compromised immune 
status, such as HIV-infected individuals [7].
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countries (France, Germany, Italy, Spain, 
the UK, Austria, Greece, Portugal, Norway, 
Sweden, Switzerland, Finland, and Denmark). 
Primary care physicians (including internists 
in Germany) and specialists (pulmonologists, 
infectious disease specialists, other specialists: 
hygienists, geriatricians, internists, preventative 
medicine specialists) participated in 30-minute 
online or face-to-face (Greece and Portugal only) 
interviews held between November 29 2010 
and January 24 2011.
Members of the general public aged 
>50 years also participated in a survey regarding 
their attitudes to vaccination. These individuals 
participated in 20-minute computer-assisted 
telephone or face-to-face interviews (in Germany 
and Spain) held between November 18 and 
December 29 2010.
This survey was conducted in accordance 
with the International Chamber of Commerce/
European Society for Opinion and Market 
Research (ICC/ESOMAR) code of practice, which 
defines ethical rules for professional market 
research companies and establishes safeguards 
for survey participants [24]. The survey 
methodology also complied with local laws and 
recommendations concerning data protection 
(e.g., in France, Article 29 of the Data Protection 
Act of 6 January 1978 amended in 2004 and the 
Commission nationale de l’informatique et des 
libertés [CNiL] recommendations [25]). Written 
informed consent was obtained from physicians 
participating via online interviews but not 
from physicians participating via face-to-face 
interviews or from members of the general 
public. Survey questions for both physicians 
and adults are available in the Supplementary 
Material (see Questionnaires 1 and 2).
This article does not contain findings from 
either interventional studies in humans or 
animal studies that have been performed by any 
of the authors.
Mortality associated with IPD increases with age 
in adults, reaching 10.6% in patients ≥65 years of 
age and 20.6% in those aged ≥80 years [10, 17]. 
The following factors have been identified as 
being associated with fatal outcomes in patients 
with IPD: increasing comorbidity scores, 
neutropenia, HIV infection, chronic respiratory 
disease, and chronic liver disease [21].
In line with the significant burden of 
pneumococcal infections, recommendations 
for vaccinating elderly and vulnerable 
individuals against pneumococcal infections 
are available in most European countries. There 
is, however, considerable variability between 
countries concerning individuals regarded 
at risk of invasive pneumococcal infections, 
and these disparities appear to impact rates 
of pneumococcal vaccination across Europe. 
Higher rates of vaccine use have been reported in 
countries with age-based recommendations and 
public reimbursement (e.g., UK) than in those 
countries only recommending at-risk individuals 
(e.g., The Netherlands, Denmark, Portugal, and 
France) [22, 23]. Lack of reimbursement may 
also explain low rates of vaccination in some 
countries (e.g., Austria, Finland, and Norway) 
with age-based recommendations [22]. 
The aim of this article is to describe the current 
level of awareness of pneumococcal infection 
among primary care physicians and specialists, 
as well as physicians’ and the general publics’ 
attitudes towards vaccination, based on findings 
from a European survey of physicians and 
individuals aged >50 years from the general public.
MATERIALS AND METHODS
Survey
A physician survey was conducted to determine 
pneumococcal disease awareness and attitudes 
to vaccination in 13 Western European 
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Participant Eligibility and Recruitment
Physicians were recruited from a European 
panel, which included 87,048 primary care 
doctors and 18,948 specialists (as defined 
above). Practicing physicians were included in 
the survey if they were aged between 30 and 
65 years (inclusive), had been in practice for 
≥3 years, and spent ≥50% of their working time 
in direct patient care. Primary care physician 
and specialist selection was based on age and sex 
distribution according to country demographics 
and regional distribution. E-mail invites were 
sent to a sample of panellists, with e-mail 
and telephone follow-up to achieve the target 
number of participants. Survey respondents 
were paid for their participation. 
Adults aged >50 years were recruited via random 
house sampling in Germany, and via interviewer 
selection, ensuring that quotas were fulfilled and 
that the individual was willing to participate, 
in Spain. Within the remaining countries, 
participants were recruited using the national 
phonebook information. The sample population 
was designed to reflect the socio-demographic 
structure of the national population available in 
each country. Adults aged >50 years who were 
representative of each country’s demographic, 
in terms of age, sex, region, and socio-economic 
level, were selected for inclusion into the survey. 
In Germany, interviews were conducted face-
to-face at the respondent’s residence. In Spain, 
qualifying participants were invited for interview 
in the street and then came to a room for the 
interview. Members of the general public did not 
receive payment for their participation. 
Both physicians and adults were excluded 
from the survey if they or someone in their 
family worked full-time in a pharmaceutical or 
market research company, or if they had taken 
part in a survey in the field of vaccination within 
the past 3 months.
Statistical Analysis
The survey findings were summarised 
descriptively with the percentage of primary 
care physicians, specialists, or individuals aged 
>50 years calculated for each response. Overall 
percentages (i.e., for all 13 countries) for each 
of these three groups were calculated, as well as 
percentages in each country. Mean frequency 
and severity scores (based on 7-point scales) 
for pneumococcal infections and some other 
common infectious diseases were also calculated 
for physicians. Statistical analysis of the levels of 
spontaneous awareness and probed awareness 
(i.e., physicians were presented with a list of 
terms) among the physicians were undertaken, 
using a two-sided t-test to compare awareness 
levels between the pneumococcal infection terms. 
RESULTS
Study Populations
A total of 1,300 primary care physicians 
(100 from each country) participated in the survey 
from each of the 13 countries. The demographics 
of the primary care physicians varied by country. 
The percentage of male primary care physicians 
ranged from 44% in Finland to 80% in Denmark, 
and the percentage of physicians aged >50 years 
ranged from 19% in Spain to 72% in Portugal. 
The proportion of primary care physicians with 
≥15 years’ experience also varied from 45% in 
Sweden to 81% in Italy.
The 926 specialists participating in the survey 
comprised a total of 86 specialists from Norway, 
Denmark, and Finland; 60 specialists each from 
Portugal, Austria, Switzerland, and Sweden; 
and 100 specialists each from the remaining 
six countries. These physicians were mostly 
respiratory specialists (ranging from 30% to 
92% depending on country) or infectious disease 
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specialists (ranging from 5% to 67%). Other 
specialists included hygienists, geriatricians (or 
internists specializing in elderly medicine), and 
preventive medicine specialists within Italy, 
Germany, or Spain, respectively. The percentage 
of male specialists ranged from 63% (Norway, 
Finland, and Denmark) to 88% (Germany). The 
proportion of specialists aged >50 years varied 
according to country (ranging from 16% in the 
UK to 58% in Sweden), as did the proportion 
with ≥15 years’ experience (30% in the UK and 
73% in Italy).
A total of 6,534 adults aged >50 years 
participated in the survey (around 500 individuals 
from each of the 13 countries). Across these 
countries, the proportion of male individuals 
varied from 45% to 50%. In Germany, 52% 
were aged ≥60 years and, within the remaining 
12 countries, between 31% (Switzerland) 
and 60% (Portugal) were aged ≥65 years. The 
proportion of retired individuals ranged from 
29% in Switzerland to 63% in France. 
Disease Awareness Among Primary Care 
Physicians and Specialists
Pneumonia was the most well-known of the 
pneumococcal infections. When physicians 
were asked to name pneumococcal infections, 
significantly more physicians named pneumonia 
than other pneumococcal infections (P < 0.001): 
78% of primary care physicians and 78% of 
specialists named pneumonia, 54% and 60% 
named meningitis, and 25% and 36% named 
sepsis/septicaemia, respectively. When presented 
with a list of pneumococcal infections, 93% of 
primary care physicians and 96% of specialists 
stated that they knew about non-invasive 
pneumococcal pneumonia (Table 1), with 
awareness levels ranging from 83% to 99% and 
91% to 100%, respectively, across the 13 countries 
(data not shown). IPD, however, was the least 
well known term (P < 0.001 for IPD vs. other 
terms); only 50% of primary care physicians 
(30–96% within specific countries) and 71% 
of specialists (56–98%) knew about this term, 
compared with awareness levels of 75–94% and 
92–97%, respectively, for individual pneumococcal 
conditions categorised as IPD: meningitis, sepsis, 
bacteraemic pneumonia, and bacteraemia.
Physicians were also asked to grade the 
severity of various infectious diseases, including 
pneumococcal infections, using a 7-point scale, 
where 7 was extremely severe and 1 was not severe 
at all. Both primary care physicians and specialists 
rated seasonal influenza as less severe than any 
of the individual pneumococcal infections 
(meningitis, sepsis, IPD, and pneumonia; Fig. 1). 
Table 1  Awareness of terms for pneumococcal infections among primary care physicians and specialistsa




Pneumococcal pneumonia (non-invasive) 93 96
Pneumococcal meningitis 94 96
Pneumococcal sepsis 91 97
Bacteraemic pneumococcal pneumonia 82 92
Pneumococcal bacteraemia 75 92
Invasive pneumococcal diseases 50* 71*
a Physicians were presented with a list of terms and asked which of them they knew. * P < 0.001 versus other terms
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The mean severity scores as rated by primary care 
physicians and specialists, respectively, varied 
from 5.7 to 6.6 and from 5.6 to 6.6 (based on the 
7-point scale) for infections classified as IPD, as well 
as for the term IPD itself. Primary care physicians 
perceived pneumococcal sepsis and meningitis as 
very severe diseases (severity score: 6.6 for both) 
compared with a severity score of 4.9 for 
non-invasive pneumococcal pneumonia. 
The frequency of pneumococcal infections 
as reported by specialists was higher than that 
reported by primary care physicians (mean 
frequency scores ranging from 2.8 to 4.7 and 
from 2.6 to 3.9, respectively, on a 7-point scale, 
Fig. 1  Perceived severity of pneumococcal infections (light blue bars) compared with other infectious diseases (dark blue 
bars) among primary care physicians and specialists. Physicians (primary care physicians: n = 1,300; specialists: n = 926) 
were asked to grade the severity of the above infectious diseases using a 7-point scale, where 7 is extremely severe and 1 is not 
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where 7 was extremely frequent), and both 
groups of physicians perceived pneumococcal 
infections to be less frequent than other vaccine-
preventable diseases such as gastroenteritis 
and influenza, which both had mean severity 
scores >5 (Fig. 2). The mean frequency scores 
for IPD (2.7 and 3.2), as rated by primary care 
physicians and specialists, respectively, were 
lower than those for non-invasive pneumococcal 
pneumonia (3.9 and 4.7) and bacteraemic 
pneumococcal pneumonia (3.3 and 3.9). 
Physicians’ Attitudes to Vaccination
Over 60% of primary care physicians and 
specialists selected the following as factors 
Fig. 2  Perceived frequency of pneumococcal infections (light blue bars) compared with other infectious diseases (dark blue 
bars) among primary care physicians and specialists. Physicians (primary care physicians: n = 1,300; specialists: n = 926) 
were asked to grade the frequency of the above infectious diseases using a 7-point scale, where 7 is extremely frequent and 1 is 
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influencing their decisions regarding adult 
vaccination overall: patient’s health condition, 
recommendations from health authorities, and 
tolerability of the vaccine (data not shown). 
For pneumococcal vaccination, the patient’s 
health condition was also a key factor for 
recommending/prescribing vaccination (rated 
6 or 7 on a 7-point scale by 74% of primary 
care physicians and specialists), as were health-
authority recommendations, the patient’s age, 
and tolerability of the vaccine (Fig. 3). When 
asked in what patient profile they would 
recommend and/or prescribe pneumococcal 
vaccination, most (≥76%) physicians selected 
at-risk or elderly individuals (Table 2, which 
includes physicians’ definitions of these groups). 
The main factors leading to a physician 
sometimes not recommending pneumococcal 
vaccination were that pneumococcal vaccination 
concerns only a subgroup of patients (selected 
by 67% and 77% of primary care physicians and 
specialists, respectively), the physician’s mind-
set (i.e., vaccination is not at the top of the 
physician’s mind), and lack of time (Table 2). 
General Public’s Attitudes to Vaccination
Of the adults aged >50 years included in the 
survey, 70%, 49%, and 10% indicated that they 
had received tetanus/diphtheria, influenza, and/or 
pneumococcal vaccines, respectively, since the age 
of 18 years (see Supplementary Material – Table 1 




Tolerability of the vaccine 55
Your personal experience of 
using the vaccine 41
Duration of protection provided 
by the vaccine 40
Patient’s request for the vaccine 34
Reimbursement of the vaccine 21
Price of the vaccine 
if not reimbursed 18










100 20 30 40 50 60 70 80 90 100
SpecialistsPrimary care physicians
Percentage of physicians Percentage of physicians
Fig. 3  Factors inuencing physicians’ decision making when recommending or prescribing pneumococcal vaccination for 
adult patients. Physicians (primary care physicians: n = 1,277; specialists: n = 891) were asked to indicate how important the 
above factors (using a 7-point scale) were when recommending or prescribing pneumococcal vaccination for adult patients. 
Figure shows percentage of physicians rating each factor 6 or 7
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for vaccination rates within each country). The 
percentage of individuals agreeing with statements 
concerning adult vaccination is shown in Table 3. 
Over 60% of individuals in each country agreed 
that adult vaccines can save lives, while ≤35% 
considered vaccines to be unnecessary for 
treatable conditions and ≤25% were concerned 
about the side effects of vaccines. Key reasons for 
adults to be vaccinated were the need to protect 
against sickness (ranked as one of their top three 
reasons by 51–86% of individuals within each 
country), recommendations from a healthcare 
professional (18–65%), and that vaccination 
provides reassurance against contracting a disease 
Table 2  Factors aecting physicians’ decision to prescribe pneumococcal vaccination in adults




Patient prole in which pneumococcal vaccination prescribeda
At-risk patientsb 93 96
Elderly patientsc 76 76
Revaccination of patients 44 43
Patients who asked for the vaccination 43 36
People who care for elderly individuals 22 24
Healthcare professionals (to avoid infection from patients) 19 23
People who care for children 12 16
Other 7 8
Reasons why physicians may not recommend or prescribe pneumococcal vaccinationd
Vaccination concerns only specic groups of adults 67 77
Vaccination is not at top of mind 30 18
Lack of time 23 14
Not wanting to spend time convincing people not in favour of 
vaccination
17 10
Not having time to discuss/explain benets of vaccine 10 6
Doubts concerning the vaccine 6 10
Doubts concerning ecacy 4 8
Doubts concerning safety 3 3
Data within table are based on two separate questions.  
a Physicians who prescribe or recommend at least one vaccine per year were asked in what prole of patients they recommend 
and/or prescribe pneumococcal vaccination. Table shows the percentage of physicians selecting each prole
b Mostly immunosuppressive or asplenic patients or those with asthma or chronic obstructive pulmonary disease
c Physicians were asked at what age they considered individuals to be elderly. e mean age for this cut-o was  
67 years (primary care physicians; 61–71 years depending on the country) or 66 years (specialists, 63–68 years depending on 
the country)
d Physicians were asked to indicate why they do not sometimes recommend or prescribe pneumococcal vaccination.  
Table shows the percentage of physicians selecting each reason
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(10–38%; Table 4). Similarly, individuals selected 
the following as key reasons for not receiving 
pneumococcal vaccines: lack of physician 
recommendation or vaccine awareness, and not 




Findings from this survey highlight the 
variability in knowledge/awareness levels of 
pneumococcal conditions amongst primary 
care physicians and specialists. Pneumonia 
was the most well-known of the pneumococcal 
infections, which is in line with the fact that 
pneumonia is the most common serious 
presentation of pneumococcal infections. 
The survey results, however, highlighted the 
relatively low knowledge of the term IPD. This 
may reflect the fact that IPD is not currently 
considered a relevant classification in everyday 
practice. This is perhaps not surprising given that 
IPD is not an ‘independent’ entity, except in rare 
cases of primary bacteraemia [26] and, also, that 
no significant differences have been identified 
in outcomes and mortality rates between CAP 
with or without pneumococcal bacteraemia [27].
Physicians within the survey considered 
pneumococcal infections to be severe. This 
is in line with morbidity and mortality data 
reported in the literature, especially in elderly 
individuals. For example, a Spanish study 
analysing hospital discharges and deaths related 
to pneumococcal pneumonia in adults aged 
>50 years between 2003 and 2007 calculated 
an annual hospitalisation rate of 1.09 cases 
per 1,000, with a case-fatality rate of 11.6% for 
pneumococcal pneumonia [28]. Similarly, a 
30-day mortality rate of 9.6% was reported in 
a UK observational study conducted in adults 
hospitalised with pneumococcal non-invasive 
CAP between 2008 and 2010 [29]. 
The perceived frequency of pneumococcal 
infections tended to be lower in primary care 
physicians than in specialists, and both groups of 
physicians perceived pneumococcal infections to 
be less frequent than other vaccine-preventable 
diseases such as gastroenteritis and influenza. The 
perceived frequency of IPD was also lower than 
that of non-invasive pneumococcal pneumonia, 
as well as bacteraemic pneumococcal pneumonia, 
which is classified as IPD. These findings could 
be attributed to the fact that confirmation 
of IPD requires investigations, such as blood 
culture, which are not routinely undertaken 
in the community or on an outpatient basis. 
Therefore, it is a diagnosis that cannot easily 
be confirmed by primary care physicians. S. 
pneumoniae is a leading cause of lower respiratory 
tract infections (LRTIs), accounting for 38% of 
outpatient cases of CAP, 27% of inpatient cases 
of CAP, and 28% of intensive-care pneumonia 
cases, according to a recent review [5]. However, 
the exact contribution of pneumococcus to CAP 
is unknown, as a definite causative agent cannot 
be identified by conventional diagnostic methods 
(such as sputum culture) in most cases. A recent 
serological study conducted in hospitalised 
patients with CAP suggests that S. pneumoniae 
may actually account for >50% of cases [30]. 
The incidence of pneumococcal infection in the 
community is unknown as most epidemiology 
studies have been conducted in hospitalised 
patients and primary care physicians will usually 
treat pneumonia without knowing the pathogen 
responsible.
Factors Influencing Vaccination
The survey also investigated physicians’ 
attitudes to vaccination. Key factors influencing 
physicians to recommend or prescribe adult 
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vaccines in general and pneumococcal vaccines 
in particular were an individual’s condition and 
age, recommendations from health authorities, 
and tolerability of the vaccine. The main drivers 
that may lead a physician to sometimes not 
recommend pneumococcal vaccination were: 
pneumococcal vaccination concerns only a 
subgroup of patients, the physician’s mind-
set, and lack of time. Doubts concerning the 
efficacy and safety of the vaccine and cost were 
low on the list of reasons against pneumococcal 
vaccination. This survey was conducted when 
PPV-23 was the only pneumococcal vaccine 
available. These findings, therefore, reflect 
the fact that PPV was reimbursed for patients 
considered to be at risk of pneumococcal 
infections in most countries included in this 
survey, and also suggest that doubts concerning 
PPV did not influence physician decision-
making concerning pneumococcal vaccination.
Amongst the adults aged >50 years included 
in the survey, perceptions regarding vaccination 
were good: individuals considered vaccines 
to be lifesaving and they did not fear vaccines 
or their side effects. The main drivers leading 
adults to be vaccinated were the need to 
protect against sickness, recommendations 
from a healthcare professional, and (to a lesser 
extent) that vaccination provides reassurance 
against contracting a disease. The main barriers 
towards pneumococcal vaccination were lack of 
physician recommendation or vaccine awareness 
and not being concerned about pneumonia/
pneumococcal infections.
There was some variability between countries 
with respect to attitudes to vaccination 
from the adults aged >50 years, which may 
reflect variations in official vaccination 
recommendations and reimbursement between 
countries. However, a limitation of this survey 
was the differing methodologies employed across 
countries in terms of participant recruitment 
and interviews, and these differences may have 
introduced bias when comparing participant 
responses between countries.
Importance of Vaccination Programmes
Given the significant burden of pneumococcal 
infections, especially in elderly individuals, 
pneumococcal vaccination should be an 
important contribution to infectious disease 
prevention in an approach to lifelong health. 
As previously discussed, recommendations for 
vaccinating elderly and vulnerable individuals 
against pneumococcal infections vary from 
country to country, and this appears to impact 
coverage levels [22]. For example, the national 
pneumococcal immunisation programme 
within the UK includes all adults aged ≥65 years 
and, according to an annual survey of English 
primary care practices, coverage of PPV within 
this age group was 68.3% in 2012 [23]. However, 
lower pneumococcal vaccination rates (20–30%) 
have been reported in other European surveys 
in elderly individuals [22, 31, 32]. In the survey 
described here, 10% of adults aged >50 years 
indicated that they had received pneumococcal 
vaccines since the age of 18 years.
Findings from European surveys also 
suggest low pneumococcal vaccination rates 
amongst individuals with immunosuppression 
or chronic diseases [32–34]. Coverage rates in 
Italy, based on data collected from local health 
unit vaccination registers between 2000 and 
2007, and cluster sampling among general 
practitioners, were around 20% in patients with 
chronic diseases [32]. Similarly, a German survey 
of immunosuppressed patients with chronic 
inflammatory diseases reported a pneumococcal 
vaccination rate of 9% [34]. Within this survey, 
there was a marked discrepancy in terms of 
patients’ willingness to be vaccinated and 
the actual provision of vaccination [34]. In a 
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French study, a 3% coverage rate was reported 
for HIV-infected individuals, with the most 
frequent reasons for non-vaccination reported 
as non-proposal by physicians, lack of expected 
effectiveness, and fear of immunovirological 
adverse effects [33].
Other surveys have suggested potential factors 
influencing pneumococcal vaccination, such 
as time spent with patients during ‘well’ visits, 
enhanced vaccination documentation, and 
patient factors (age, comorbidities, and quality 
of life) [35, 36]. The general misconception 
that vaccination is an issue for early life/
childhood can be another barrier to adult 
vaccination. Patient-related barriers (e.g., fear 
of adverse events or injections) and healthcare 
professional-related issues (e.g., failure to 
endorse vaccination) have also been identified as 
factors influencing adult vaccination rates [37]. 
Low adult vaccination rates have led the 
European Union Geriatric Medicine Society and 
the International Association of Gerontology 
and Geriatrics to develop guidelines on 
vaccination of elderly individuals, with the aim 
of increasing adult vaccination coverage across 
Europe, thereby promoting healthy ageing by 
limiting the burden of vaccine-preventable 
infectious diseases [37]. 
Vaccination rates can be improved by nurse-
led programmes [38] or by administering 
pneumococcal vaccine when the patient attends 
the clinic for their annual influenza vaccination 
[39]. Computer systems, such as those used within 
the UK, that identify patients who have not 
been vaccinated and flag this information to the 
clinician within the clinical notes, may also help 
improve vaccination rates by allowing primary care 
physicians to promote pneumococcal vaccination 
at each patient visit. Pneumococcal infection 
awareness campaigns for the general public are 
a key initial step in improving vaccination rates 
amongst patients at risk [37]. 
PPVs have been available since 1983 and have 
been shown to reduce IPD in adults. However, 
data concerning the use of PPVs to prevent 
pneumococcal pneumonia or mortality are 
less clear [12, 40]. Specifically, there is limited 
evidence that PPV-23 is protective against 
pneumonia in elderly individuals or patients 
with chronic respiratory diseases, for whom the 
vaccine is recommended in many industrialised 
countries [40]. Over the past decade, a 7-valent 
PCV (PCV-7) has been available globally as part 
of a pneumococcal vaccination programme 
in children, and has resulted in a significant 
decrease in both IPD and mucosal disease in 
children [41–45] as well as also lower levels of 
antibiotic resistance [46]. There is evidence that 
elderly individuals have also, indirectly, benefited 
from this programme [47–50]. Higher-valent 
pneumococcal conjugate vaccines (PCV-10, 
PCV-13) have been available for use in infants 
and children in some countries since 2009 [44]. 
In Europe, PCV-13 is now available in some 
countries for the prevention of IPD in 
individuals aged >50 years [51], and for the 
prevention of IPD, pneumonia, and otitis media 
in infants and children from 6 weeks up to the 
age of 17 years [52]. PCV-10 is also available 
in Europe for immunisation against IPD and 
acute otitis media in infants and children from 
6 weeks up to 5 years of age [53].
Immunological responses following PCV-13 
vaccination, as measured by functional 
opsonophagocytic activity, have been 
demonstrated to be at least as good as those 
following PPV-23 for all serotypes, and 
significantly higher for 9/13 serotypes, in 
pneumococcal vaccine-naïve individuals aged 
60–64 years [54, 55]. PCV-13 re-vaccination, 
following either PCV-13 or PPV-23 vaccination, 
also results in renewed immunological response 
similar to that observed following the first 
PCV-13 dose. 
402 Adv Ther (2013)  30(4):387–405.
Endre Ludwig has received honoraria for 
participating in advisory boards and giving 
lectures for Pfizer, Bayer, Astellas, MSD, and 
Novartis. George Kassianos has received honoraria 
for participating in advisory boards and/or giving 
lectures for AstraZeneca, Abbott, Bayer, Crucell/
Janssen, GSK, MSD, Pfizer, Sanofi Pasteur MSD, 
and Sigma-Tau.
Compliance with Ethics Guidelines. This 
survey was conducted in accordance with the 
International Chamber of Commerce/European 
Society for Opinion and Market Research (ICC/
ESOMAR) code of practice, which defines 
ethical rules for professional market research 
companies and establishes safeguards for survey 
participants. The survey methodology also 
complied with local laws and recommendations 
concerning data protection (e.g., in France, 
Article 29 of the Data Protection Act of 6 January 
1978 amended in 2004 and the Commission 
nationale de l’informatique et des libertés [CNiL] 
recommendations). This article does not contain 
findings from either interventional studies 
in humans or animal studies that have been 
performed by any of the authors. 
Open Access. This article is distributed 
under the terms of the Creative Commons 
Attribution Noncommercial License which 
permits any noncommercial use, distribution, 
and reproduction in any medium, provided the 
original author(s) and source are credited.
REFERENCES
1. Htwe TH, Mushtaq A, Robinson SB, Rosher RB, 
Khardori N. Infection in the elderly. Infect Dis Clin 
North Am. 2007;21:711–43, ix.
2. Liang SY, Mackowiak PA. Infections in the elderly. 
Clin Geriatr Med. 2007;23:441–56, viii.
3. Gusmano MK, Michel JP. Life course vaccination 
and healthy aging. Aging Clin Exp Res. 
2009;21:258–63.
CONCLUSION
In summary, the survey findings reported 
here indicate a low awareness of the term IPD 
amongst primary care physicians. In contrast, 
there was greater awareness of pneumonia and 
of the individual pneumococcal conditions 
categorised as IPD, such as meningitis, sepsis, 
bacteraemic pneumonia, and bacteraemia. The 
survey findings also highlight the importance 
of physician recommendations for vaccination 
in encouraging patients to be vaccinated. 
There is, therefore, a need for primary care 
physicians to be more vigilant of patients at risk 
of pneumococcal infection in order to increase 
vaccination rates.
ACKNOWLEDGMENTS
This research was sponsored by Pfizer, Paris, 
France. The survey was administered by IPSOS 
Healthcare, Paris, France. The authors take full 
responsibility for the content of this article and 
thank Joanne Vaughan (Neostar Communications 
Ltd, Oxford, UK; funded by Pfizer, Paris, France) 
for her assistance in preparing the manuscript, 
including preparing the first draft in close 
collaboration with the authors and the collation 
of author comments. Pfizer also paid the article 
processing charges. The authors would also like 
to thank Olivia Bussod and Lídia Oliveira (Pfizer, 
France) for their comments and suggestions on 
the drafts of this manuscript and also Olivia 
Bussod for her involvement in the development 
of the survey. The authors did not receive 
honoraria in relation to the preparation of this 
manuscript. Dr. Kassianos is the guarantor for this 
article, and takes responsibility for the integrity of 
the work as a whole.
Conflict of interest. Hartmut Lode is a 
speaker and scientific adviser for Astellas, Bayer, 
OM Pharma, Novartis, Pfizer, Sanofi, and GSK. 
Adv Ther (2013)  30(4):387–405. 403
vaccination uptake: surveillance in Hull and East 
Yorkshire, UK, 2002–2009. Epidemiol Infect. 
2012;140:1252–66.
17. Kyaw MH, Christie P, Clarke SC, et al. Invasive 
pneumococcal disease in Scotland, 1999–2001: use 
of record linkage to explore associations between 
patients and disease in relation to future vaccination 
policy. Clin Infect Dis. 2003;37:1283–91.
18. Trotter CL, Waight P, Andrews NJ, et al. 
Epidemiology of invasive pneumococcal disease in 
the pre-conjugate vaccine era: England and Wales, 
1996–2006. J Infect. 2010;60:200–8.
19. Jansen AG, Rodenburg GD, de Greeff SC, et al. 
Invasive pneumococcal disease in the Netherlands: 
syndromes, outcome and potential vaccine 
benefits. Vaccine. 2009;27:2394–401.
20. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology 
of invasive pneumococcal disease among adult 
patients in Barcelona before and after pediatric 
7-valent pneumococcal conjugate vaccine 
introduction, 1997–2007. Clin Infect Dis. 
2009;48:57–64.
21. Giner AM, Kuster SP, Zbinden R, Ruef C, 
Ledergerber B, Weber R. Initial management of 
and outcome in patients with pneumococcal 
bacteraemia: a retrospective study at a Swiss 
university hospital, 2003–2009. Infection. 
2011;39:519–26.
22. Fedson DS, Nicolas-Spony L, Klemets P, et al. 
Pneumococcal polysaccharide vaccination for 
adults: new perspectives for Europe. Expert Rev 
Vaccines. 2011;10:1143–67.
23. Department of Health. Pneumococcal 
polysaccharide vaccine (PPV) uptake summary 
report. Available at: http://immunisation.dh.gov.
uk/ppv-uptake-report-2012. Accessed Apr 9 2013.
24. World ESOMAR Research, ICC. ICC/ISOMAR 
International Code on market and social research. 
ESOMAR 2007. Available at: http://www.esomar.
org/uploads/public/knowledge-and-standards/
codes-and-guidelines/ESOMAR_ICC-ESOMAR_
Code_English.pdf. Accessed Mar 27 2013.
25. CNIL. Decree No 2005–1309 of 20 October 2005 
enacted for the application of Act No 78-17 of 
6 January 1978 on Data Processing, Files and 
Individual Liberties (Amended by Decree 2007-451 
of 25 March 2007) Consolidated on the 25th of 
March 2007. CNIL 2007. Available at: http://www.
cnil.fr/fileadmin/documents/en/Decree%202005-
1309.pdf. Accessed Mar 27 2013.
4. Gavazzi G, Krause KH. Ageing and infection. 
Lancet Infect Dis. 2002;2:659–66.
5. Welte T, Torres A, Nathwani D. Clinical and 
economic burden of community-acquired 
pneumonia among adults in Europe. Thorax. 
2012;67:71–9.
6. Weiskopf D, Weinberger B, Grubeck-Loebenstein 
B. The aging of the immune system. Transpl Int. 
2009;22:1041–50.
7. Blasi F, Mantero M, Santus P, Tarsia P. Understanding 
the burden of pneumococcal disease in adults. Clin 
Microbiol Infect. 2012;18:7–14.
8. Sjostrom K, Spindler C, Ortqvist A, et al. Clonal 
and capsular types decide whether pneumococci 
will act as a primary or opportunistic pathogen. 
Clin Infect Dis. 2006;42:451–9.
9. Reinert RR, Haupts S, van der Linden M, et al. 
Invasive pneumococcal disease in adults in North-
Rhine Westphalia, Germany, 2001–2003. Clin 
Microbiol Infect. 2005;11:985–91.
10. Robinson KA, Baughman W, Rothrock G, et 
al. Epidemiology of invasive Streptococcus 
pneumoniae infections in the United States, 
1995–1998: opportunities for prevention in the 
conjugate vaccine era. JAMA. 2001;285:1729–35.
11. Fung HB, Monteagudo-Chu MO. Community-
acquired pneumonia in the elderly. Am J Geriatr 
Pharmacother. 2010;8:47–62.
12. Moberley SA, Holden J, Tatham DP, Andrews 
RM. Vaccines for preventing pneumococcal 
infection in adults. Cochrane Database Syst Rev. 
2008;CD000422.
13. Siemieniuk RA, Gregson DB, Gill MJ. The persisting 
burden of invasive pneumococcal disease in HIV 
patients: an observational cohort study. BMC 
Infect Dis. 2011;11:314.
14. Yin Z, Rice BD, Waight P, et al. Invasive 
pneumococcal disease among HIV-positive 
individuals, 2000–2009. AIDS. 2012;26:87–94.
15. Grau I, Ardanuy C, Linares J, Podzamczer D, 
Schulze MH, Pallares R. Trends in mortality and 
antibiotic resistance among HIV-infected patients 
with invasive pneumococcal disease. HIV Med. 
2009;10:488–95.
16. Elston JW, Santaniello-Newton A, Meigh JA, et al. 
Increasing incidence of invasive pneumococcal 
disease and pneumonia despite improved 
404 Adv Ther (2013)  30(4):387–405.
36. Krueger P, St Amant O, Loeb M. Predictors of 
pneumococcal vaccination among older adults 
with pneumonia: findings from the Community 
Acquired Pneumonia Impact Study. BMC Geriatr. 
2010;10:44.
37. Michel JP. Updated vaccine guidelines for aging 
and aged citizens of Europe. Expert Rev Vaccines. 
2010;9:7–10.
38. Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, 
Johnson JA. Interventions to improve influenza 
and pneumococcal vaccination rates among 
community-dwelling adults: a systematic review 
and meta-analysis. Ann Fam Med. 2012;10:538–46.
39. Badertscher N, Morell S, Rosemann T, Tandjung R. 
General practitioners’ experiences, attitudes, and 
opinions regarding the pneumococcal vaccination 
for adults: a qualitative study. Int J Gen Med. 
2012;5:967–74.
40. Huss A, Scott P, Stuck AE, Trotter C, Egger M. 
Efficacy of pneumococcal vaccination in adults: a 
meta-analysis. CMAJ. 2009;180:48–58.
41. Foster D, Walker AS, Paul J, et al. Reduction 
in invasive pneumococcal disease following 
implementation of the conjugate vaccine in the 
Oxfordshire region, England. J Med Microbiol. 
2011;60:91–7.
42. Pilishvili T, Lexau C, Farley MM, et al. Sustained 
reductions in invasive pneumococcal disease in the 
era of conjugate vaccine. J Infect Dis. 2010;201:32–41.
43. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May 
L, Klugman KP. Impact of pneumococcal conjugate 
vaccination of infants on pneumonia and influenza 
hospitalization and mortality in all age groups in 
the United States. MBio. 2011;2:e00309–10.
44. Reinert RR, Paradiso P, Fritzell B. Advances 
in pneumococcal vaccines: the 13-valent 
pneumococcal conjugate vaccine received market 
authorization in Europe. Expert Rev Vaccines. 
2010;9:229–36.
45. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in 
acute otitis media-related health care utilization 
by privately insured young children in the United 
States, 1997–2004. Pediatrics. 2008;121:253–60.
46. Cohen R, Levy C, de La Rocque F, et al. Impact of 
pneumococcal conjugate vaccine and of reduction 
of antibiotic use on nasopharyngeal carriage 
of nonsusceptible pneumococci in children 
with acute otitis media. Pediatr Infect Dis J. 
2006;25:1001–7.
26. Musher DM. Pneumococcal infections. In: Kasper 
DL, Fauci AS, eds. Harrison’s Infectious Diseases. 
McGraw Hill Medical; 2010:374–85.
27. Bordon J, Peyrani P, Brock GN, et al. The 
presence of pneumococcal bacteraemia does 
not influence clinical outcomes in patients with 
community-acquired pneumonia: results from the 
Community-Acquired Pneumonia Organization 
(CAPO) International Cohort study. Chest. 
2008;133:618–24.
28. Gil-Prieto R, Garcia-Garcia L, Alvaro-Meca A, 
Mendez C, Garcia A, de Miguel AG. The burden 
of hospitalisations for community-acquired 
pneumonia (CAP) and pneumococcal pneumonia 
in adults in Spain (2003–2007). Vaccine. 
2011;29:412–6.
29. Bewick T, Sheppard C, Greenwood S, et al. 
Serotype prevalence in adults hospitalised with 
pneumococcal non-invasive community-acquired 
pneumonia. Thorax. 2012;67:540–5.
30. van Mens SP, Meijvis SC, Endeman H, et al. 
Longitudinal analysis of pneumococcal antibodies 
during community-acquired pneumonia reveals 
a much higher involvement of Streptococcus 
pneumoniae than estimated by conventional 
methods alone. Clin Vaccine Immunol. 
2011;18:796–801.
31. Gavazzi G, Wazieres B, Lejeune B, Rothan-Tondeur 
M. Influenza and pneumococcal vaccine coverages 
in geriatric health care settings in France. 
Gerontology. 2007;53:382–7.
32. Martinelli D, Tafuri S, Caputi G, et al. Eight years 
of active proposal of pneumococcal 23-valent 
polysaccharide vaccine: survey on coverage rate 
among elderly and chronic patients. Am J Infect 
Control. 2010;38:e8–e15.
33. Mohseni-Zadeh M, Rey D, Batard ML, et al. 
Inadequate vaccination coverage in a French 
cohort of HIV positive patients [In French]. Med 
Mal Infect. 2010;40:683–90.
34. Teich N, Klugmann T, Tiedemann A, et al. 
Vaccination coverage in immunosuppressed 
patients: results of a regional health 
services research study. Dtsch Arztebl Int. 
2011;108:105–11.
35. Zimmerman RK, Nowalk MP, Tabbarah M, Hart 
JA, Fox DE, Raymund M. Understanding adult 
vaccination in urban, lower-socioeconomic 
settings: influence of physician and prevention 
systems. Ann Fam Med. 2009;7:534–41.
Adv Ther (2013)  30(4):387–405. 405
52. European Medicines Agency. Prevenar 13. European 




Accessed Mar 4 2013.
53. GlaxoSmithKline Biologicals s.a. Synoflorix. 
Summary of product characteristics. European 
Medicines Agency 2013. Available at: http://www.
ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Product_Information/human/000973/
WC500054346.pdf. Accessed Mar 4 2013.
54. Jackson LA, Gurtman A, van Cleeff M. 
Immunogenicity and safety of a 13-valent 
pneumococcal conjugate caccine in pneumococcal 
vaccine naive adults, 50-64 years of age [abstract 
O426]. Clin Microbiol Infect. 2011;17:S85. 
55. Jackson LA, Gurtman A, van Cleeff M. 13-valent 
pneumococcal conjugate vaccine (PCV13) 
enhances the response to subsequent PCV13 and 
23-valent pneumococcal polysaccharide (PPSV23) 
vaccinations in adults 50 years and older [abstract 
LB-3]. Presented at the 49th Annual Meeting of the 
Infectious Diseases Society of America; October 20–
23, 2011; Boston, MA.
47. Whitney CG, Farley MM, Hadler J, et al. Decline 
in invasive pneumococcal disease after the 
introduction of protein-polysaccharide conjugate 
vaccine. N Engl J Med. 2003;348:1737–46.
48. Lexau CA, Lynfield R, Danila R, et al. Changing 
epidemiology of invasive pneumococcal disease 
among older adults in the era of pediatric 
pneumococcal conjugate vaccine. JAMA. 
2005;294:2043–51.
49. Miller E, Andrews NJ, Waight PA, Slack MP, George 
RC. Herd immunity and serotype replacement 
4 years after seven-valent pneumococcal 
conjugate vaccination in England and Wales: an 
observational cohort study. Lancet Infect Dis. 
2011;11:760–8.
50. Myint TT, Madhava H, Balmer P, et al. The impact 
of 7-valent pneumococcal conjugate vaccine on 
invasive pneumococcal disease: a literature review. 
Adv Ther. 2013;30:127–51.
51. Pfizer Limited. Prevenar 13 suspension for 
injection summary of product characteristics. 
eMC. Available at: http://www.medicines.org.uk/
emc/medicine/22689/SPC/Prevenar+13+suspensio
n+for+injection/. Accessed Feb 4 2013.
